Achieving sufficient delivery across the blood–brain barrier is a key challenge in the
development of drugs to treat central nervous system (CNS) disorders. This is particularly …

Loss-of-function heterozygous mutations in GRN, the gene encoding progranulin (PGRN),
were identified in patients with frontotemporal lobar degeneration (FTLD) almost two …

Bacteria can bypass the blood-brain barrier (BBB), suggesting the possibility of employment
of bacteria for combating central nervous system diseases. Herein, we develop a bacteria …

Antibodies are essential components of an adaptive immune response. Immunoglobulin G
(IgG) is the most common type of antibody found in circulation and extracellular fluids …

Effective delivery of protein therapeutics to the central nervous system (CNS) has been
greatly restricted by the blood-brain barrier (BBB). We describe the development of a BBB …

In the past decade, evidence for a fluid clearance pathway in the central nervous system
known as the glymphatic system has grown. According to the glymphatic system concept …

The function of B cells in Alzheimer's disease (AD) is not fully understood. While
immunoglobulins that target amyloid beta (Aβ) may interfere with plaque formation and …

Obtaining efficient drug delivery to the brain remains the biggest challenge for the
development of therapeutics to treat diseases of the central nervous system. The main …

Abstract Antibody–drug conjugates (ADCs), a class of targeted cancer therapeutics
combining monoclonal antibodies with a cytotoxic payload via a chemical linker, have …

Alzheimer's disease (AD) is the most common form of dementia. AD brain pathology starts
decades before the onset of clinical symptoms. One early pathological hallmark is blood …